论文部分内容阅读
目的:评价万古霉素对耐甲氧西林金黄色葡萄球菌(MRSA)老年呼吸机相关肺炎患者的疗效及对降钙素原水平的影响。方法:选取2014年1月—2015年2月间MRSA老年呼吸机相关肺炎患者200例,按治疗方式的不同将其分为观察组患者100例和对照组患者100例;观察组患者均给予万古霉素治疗,对照组患者均给予替考拉宁治疗,分析两组患者治疗后的总有效率以及治疗前后C反应蛋白及降钙素原水平的变化情况。结果:观察组患者治疗后的总有效率为95.00%明显高于对照组为84.00%(P<0.05);两组患者治疗后C反应蛋白明显低于治疗前(P<0.01);观察组患者治疗后C反应蛋白测定值为(62.256±7.02)mg/L明显低于对照组为(86.22±7.45)mg/L(P<0.01);两组患者治疗后降钙素原水平值为均明显低于治疗前(P<0.01);观察组患者治疗后降钙素原水平均明显低于对照组(P<0.01)。结论:万古霉素用于治疗MRSA老年呼吸机相关肺炎患者的疗效优于替考拉宁的疗效,前者能有效降低患者C反应蛋白及降钙素原水平,患者预后效果较佳。
Objective: To evaluate the efficacy of vancomycin in the treatment of MRSA patients with senile ventilator-associated pneumonia and its effect on the level of procalcitonin. Methods: 200 patients with MRSA aged ventilator-associated pneumonia were selected from January 2014 to February 2015. The patients were divided into observation group (100 cases) and control group (100 cases) according to different treatment methods. Patients in observation group The patients in the control group were treated with teicoplanin. The total effective rate and C-reactive protein and procalcitonin levels before and after treatment were analyzed. Results: The total effective rate of the observation group was 95.00%, which was significantly higher than that of the control group (84.00%, P <0.05). The C-reactive protein in the two groups was significantly lower than that before treatment (P <0.01) The level of C-reactive protein was (62.256 ± 7.02) mg / L after treatment was significantly lower than that of the control group (86.22 ± 7.45) mg / L (P <0.01) (P <0.01). The procalcitonin levels in the observation group were significantly lower than those in the control group (P <0.01). CONCLUSIONS: Vancomycin is superior to teicoplanin in the treatment of elderly patients with ventilator-associated pneumonia in elderly patients with MRSA. The former can effectively reduce the level of C-reactive protein and procalcitonin, and the prognosis of patients with advanced MRSA is better.